Table 1 Plasma pharmacokinetic parameters (mean ± SD) for triclabendazole sulphoxide (TCBZ.SO) and triclabendazole sulphone (TCBZ.SO2) obtained after the intraruminal (i.r.) administration of triclabendazole (TCBZ, 10 mg/kg, i.r.) alone or co-administered with ivermectin (IVM, 0.2 mg/kg, s.c.) and methimazole (MTZ, 1.5 mg/kg, i.m.) to Fasciola hepatica-infected sheep.
PHARMACOKINETIC PARAMETERS | TCBZ.SO | TCBZ.SO2 | ||
|---|---|---|---|---|
TCBZ alone | Combined treatment | TCBZ alone | Combined treatment | |
Cmax (μg/ml) | 14.0 ± 0.85 | 15.6 ± 1.46 | 13.5 ± 1.68 | 12.3 ± 1.28 |
Tmax (h) | 22.5 ± 7.55 | 24.0 ± 4.90 | 39.0 ± 6.00 | 42.0 ± 6.93 |
AUC0-t(μg.h/ml) | 653.9 ± 140.6 | 650.7 ± 122.8 | 868.2 ± 217.6 | 893.7 ± 114.1 |
AUC0-∞ (μg.h/ml) | 661.5 ± 148.5 | 657.1 ± 119.4 | 917.9 ± 270.6 | 945.6 ± 129.3 |
T1/2el (h) | 17.5 ± 8.45 | 18.4 ± 5.82 | 26.8 ± 10.9 | 30.4 ± 9.30 |
MRT (h) | 38.8 ± 10.5 | 39.1 ± 5.03 | 61.3 ± 17.2 | 67.6 ± 9.71 |
T1/2for (h) | 6.85 ± 2.18 | 8.26 ± 1.22 | 12.3 ± 2.90 | 13.5 ± 1.93 |